GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Scinai Immunotherapeutics SCNI · USD

Information Technology · US listing · 🇺🇸 United States

Compare

0.46

+4.85%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Scinai Immunotherapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Scinai Immunotherapeutics is based in Jerusalem, Israel and is incorporated in Israel. Its shares trade on Nasdaq under the ticker SCNI. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2022, it reported a net loss of $5.8m. At that date it held total assets of $27.1m and shareholders' equity of −$1.8m.

Read the filing on SEC.gov ↗

Company facts

Sector
Information Technology
Industry
Semiconductors & Semiconductor Equipment
Listed since
12 May 2015
Employees
45
Website
scinai.com ↗
Head office
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, L3, 00000
Incorporated in
L3
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Scinai Immunotherapeutics Ltd. has a strong focus on IL-17 NanoAb for psoriasis treatment in Israel.
  • The company collaborates with Max Planck Society and University Medical Center Gottingen for NanoAb development.
  • Scinai offers contract development services including cGMP manufacturing for biotech clients.

Weaknesses

  • Scinai Immunotherapeutics Ltd. has only 45 employees, which may limit its operational capacity.
  • The company's headquarters in Jerusalem could pose logistical challenges for international operations.
  • Scinai's business is primarily based in Israel, restricting its global market reach.

Opportunities

  • Scinai Immunotherapeutics Ltd. can expand its PC111 antibody program for pemphigus treatment globally.
  • The company's collaboration with Recipharm Israel Ltd. may lead to new biologics development opportunities.
  • Scinai can leverage its contract manufacturing services to attract more early-stage biotech clients.

Threats

  • Scinai Immunotherapeutics Ltd. faces competition from established biopharmaceutical companies in the US market.
  • The company's reliance on a single product platform (IL-17 NanoAb) increases market vulnerability.
  • Scinai's limited employee count may hinder its ability to respond to regulatory changes in the industry.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.